(NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY) are both eyeing the same pie, and they're both serious about getting a big slice. But it isn't a hot market for drugs to treat a single disease that's in dispute. It's the market for antibody-drug conjugates (ADCs), an emerging but proven therapeutic modality that should really take off through the rest of the decade after a successful first act.

The stakes for shareholders are on the higher side. Per a report by DataM Intelligence, the market for ADCs will reach a size of $16.6 billion by 2030, more than tripling its value of around $5 billion today. So who will win the confrontation, and what should investors do about it?

Let's do a quick recap of the key scientific idea here. Antibody-drug conjugates are medicines that use an antibody as both a homing device and a carrier, to deliver a therapeutic molecule as a payload to a specific physiological target. So far, all ADCs on the market are intended to treat various cancers.

Continue reading

Source Fool.com